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Cognitive impairment and levodopa 
induced dyskinesia in Parkinson’s 
disease: a longitudinal study 
from the PACOS cohort
Antonina Luca1,4, Roberto Monastero 2,4*, Roberta Baschi2, Calogero Edoardo Cicero1, 
Giovanni Mostile1, Marco Davì2, Vincenzo Restivo3, Mario Zappia1 & Alessandra Nicoletti 1*
Aim of the study was to evaluate possible associations between cognitive dysfunctions and 
development of Levodopa Induced Dyskinesia (LID). PD patients from the Parkinson’s disease 
Cognitive impairment Study cohort who underwent a baseline and follow-up neuropsychological 
evaluations were enrolled. Mild Cognitive Impairment (PD-MCI) was diagnosed according to MDS 
level II criteria. The following cognitive domains were evaluated: episodic memory, attention, 
executive function, visuo-spatial function and language. A domain was considered as impaired when 
the subject scored 2 standard deviation below normality cut-off values in at least one test for each 
domain. Levodopa equivalent dose, UPDRS-ME and LID were recorded at baseline and follow-up. To 
identify possible neuropsychological predictors associated with the probability of LID development at 
follow-up, Cox proportional-hazards regression model was used. Out of 139 PD patients enrolled (87 
men, mean age 65.7 ± 9.4), 18 (12.9%) were dyskinetic at baseline. Out of 121 patients non-dyskinetic 
at baseline, 22 (18.1%) developed LID at follow-up. The impairment of the attention and executive 
domains strongly predicted the development of LID (HR 4.45;95%CI 1.49–13.23 and HR 3.46; 95%CI 
1.26–9.48 respectively). Impairment of the attention and executive domains increased the risk of 
dyskinesia reflecting the alteration of common cortical network.
Levodopa and dopamine agonists represent the gold-standards for the management of motor symptoms of 
Parkinson’s disease (PD). Even if their efficacy is undisputed, long-term replacement therapy leads frequently to 
some motor complications such as wearing-off, on–off fluctuations, dose failure and levodopa-induced dyskinesia 
(LID), worsening the patient’s quality of  life1. LID, which includes a variety of involuntary movements ranging 
from chorea to dystonia, increases with levodopa exposure and affects about 40% of treated PD  patients2. From 
a pathophysiological point of view, LID has been related to an overactivation of the motor cortex through the 
disinhibition of the thalamocortical neurons exerted by  levodopa3. Moreover, the cortical structures involved in 
motor program and inhibition such as the supplementary motor area and the inferior frontal cortex have been 
found to be structurally and functionally impaired in PD patients with  LID3.
As the name itself suggests, levodopa is necessary but not enough to generate LID. The latter is caused by 
the pre-synaptic nigro-striatal degeneration which characterizes PD and increases along with disease duration, 
being associated with a relatively spared post-synaptic nigrostriatal system. This pathological explanation has 
been supported by data from a longitudinal study, carried out in parkinsonian patients from sub-Saharan region, 
which showed that LID frequency was more influenced by disease duration and levodopa dose rather than by the 
timing of levodopa initiation (early or delayed)4. Nevertheless, several additional risk factors associated with LID 
have been reported, including anxiety, rigid-akinetic phenotype, low body mass index, polymorphisms located 
in the dopamine receptor D2 gene, coffee consumption and female  gender5–8. Recently, an association between 
LID and cognitive impairment has been supposed but not fully  elucidated9–11.
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Aim of the present study was to evaluate the presence of possible associations between cognitive impairment 
and the occurrence of LID. This study is part of The PArkinson’s disease COgnitive impairment Study (PACOS), 
an observational study involving two Sicilian centers, aimed to assess epidemiologic, clinic and instrumental bio-
markers associated with Mild Cognitive Impairment (MCI) in a large hospital-based cohort of PD  patients12–17.
Methods
Study population. PD patients diagnosed according to the Brain Bank  criteria18, who attended the Neu-
rologic Unit of the “Policlinico Vittorio Emanuele” in Catania and the Memory and Parkinson’s disease Center 
of the “Policlinico Paolo Giaccone” in Palermo, were enrolled in the PACOS cohort, which includes 659 non-
demented PD patients at baseline. As previously  reported14, we selected all PD patients (n = 139) who under-
went at least two comprehensive neuropsychological evaluations (baseline and follow-up) during a period of 
maximum 48 months (between 12 and 48 months). Background and methods have been described elsewhere 
in  details12–14.
All participants provided written informed consent prior to be enrolled in the study, which was approved by 
Local Ethical Committee of the University Hospital of Palermo, P. Giaccone (approval number: 14:03/2018) and 
was in accordance with the Declaration of Helsinki.
Clinical and neuropsychological assessment. At baseline and at follow-up, all the enrolled patients 
were evaluated by movement disorders specialists with a standard neurological examination. Demographic, 
clinical and pharmacological data were collected from patient’s medical records. PD severity was evaluated in 
“off ” state with the Unified Parkinson Disease Rating Scale – Motor Examination (UPDRS-ME) and the Hoehn 
and Yahr (HY) scale. Levodopa Equivalent Daily Dosage (LED)19 was calculated both at baseline and at follow-
up evaluations. The presence of dyskinesia was defined at baseline and at follow-up according to the item 32 of 
the UPDRS section IV. PD patients were divided into patients without LID (LID-) and those with LID (LID +). 
At baseline patients LID + were classified as having troublesome dyskinesias according to a score ≥ 2 of the item 
33 of the UPDRS section IV.
All PD subjects underwent a comprehensive neuropsychological and behavioral assessment when in “on” state. 
Neuropsychological evaluations were performed by neurologists with a specific expertise in neuropsychology 
and dementia, and the same rater performed both baseline and follow-up assessments.
According to MDS level II criteria, the following five cognitive domains were evaluated with two tests for 
domain: episodic memory (Rey’s Auditory Verbal Learning Test and Prose recall test with a delayed recall con-
dition); attention (Stroop color-word test and Trail Making Test part A); executive functioning (Verbal fluency 
letter test and Colored Raven’s Progressive Matrices); the visuo-spatial functioning (Clock drawing test and Copy 
of figures); language (Aachener Aphasie Test-Naming item and the short version of the Token test). A domain 
was considered as “impaired” when the patient scored 2 standard deviations below normality cut-off values in 
at least one test in the specific domain, regardless the presence of MCI. Diagnosis of PD-MCI was made accord-
ing to the Movement Disorder Society Task Force criteria-level  II20. Diagnosis of PDD was made according to 
the MDS  criteria21.
Details about the neuropsychological assessment performed in the PACOS cohort have been extensively 
reported  elsewhere12–14.
Statistical analysis. Data were analysed using STATA 12.1 software packages (StataCorp. 2011. Stata Sta-
tistical Software: Release 12. College Station, TX: StataCorp LP). Data cleaning was performed before the data 
analysis considering both range and consistence checks. Quantitative variables were described using mean and 
standard deviation. The difference between means and proportions was evaluated by the t-test and the Chi 
square test, respectively. In case of a not-normal distribution, appropriate non-parametric tests were performed.
A first analysis was carried out considering all the enrolled patients at baseline. We also performed two dif-
ferent time to event analysis. From the one hand, we evaluated the role of the impairment in a specific cognitive 
domain at baseline and the risk of LID at follow-up (outcome variable) and, on the other hand, we have also 
evaluated the relationship between the presence of LID at baseline and the risk of cognitive impairment (PD-
MCI and PDD) at follow-up. Cox proportional-hazards regression model was used for both the univariate and 
multivariate analyses. Variables with p value < 0.1 at univariate analysis were included in the final multivariate 
Cox models. Schoenfeld residuals test was used for testing the proportional hazard. 95% confidence interval (CI), 
and p value (two-tailed test, a = 0.05) were calculated. Whenever variables were dichotomized or polychotomized, 
the cut-offs were derived from the pooled distribution of case and control subjects (e.g., using the median value).
Results
Baseline characteristics of the sample. As previously reported, 139 PD patients (87 men, 62.6%) with 
a mean age of 65.7 ± 9.4 and a mean disease duration of 3.0 ± 2.8 years who underwent at least two neuropsycho-
logical evaluations between 12 and 48 months were enrolled in the present study. The mean UPDRS-ME score 
was 26.2 ± 13.5 and the mean Hoehn and Yahr stage was 2.0 ± 0.7. At baseline, 84 (60.4%) were PD with normal 
cognition (PD-NC), while 55 (39.6%) fulfilled the MDS-level II diagnostic criteria for PD-MCI. Of the 139 PD 
patients at baseline 18 (12.9%) presented LID (Table 1) and among them 11 (61.1%) had troublesome LID. At 
baseline, depending on the presence of at least one test altered in a specific domain, independently from the 
presence of MCI or not, the memory domain was impaired in 41 (29.5%) PD patients, the executive functioning 
domain in 40 (28.8%) , the visuo-perceptual domain in 23 (16.5%), the attention domain in 40 (28.8%), and the 
language domain was impaired in 2 (1.4%) PD patients.
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Cognitive impairment and risk of LID. Out of the 121 patients without LID at baseline, 22 (18.1%) 
developed LID at follow-up (LID +); the mean follow-up time was 24.0 ± 10.2 months. At univariate Cox pro-
portional hazard regression models, disease duration, UPDRS-ME, LED at baseline, education and the impaired 
attentive domain were significantly associated with the development of LID, as reported in Table 2.
At multivariate analysis, adjusting by age and sex considered as a priori confounders, UPDRS-ME, LED at 
baseline and education predicted the development of LID, while the impaired executive functioning domain 
at baseline was borderline significantly associated with the development of LID (HR 2.45; 95%CI 0.89–6.71; p 
value 0.08). However, when analysis was adjusted by LED at follow-up, rather than at baseline, a stronger and 
Table 1.  Demographic and clinical characteristics at baseline. LID: levodopa induced dyskinesia; UPDRS-ME: 





N = 18 p value
Male, n (%) 77 (63.6) 10 (55.6) 0.5
Age, years 66.3 ± 9.1 61.9 ± 10.9 0.07
Age at onset, years 63.7 ± 9.4 56.3 ± 11.8 0.005
Disease duration, years 2.6 ± 2.5 5.7 ± 3.2  < 0.0001
UPDRS-ME score 24.7 ± 12.5 36.0 ± 14.8 0.002
LED mg/day 266.5 ± 285.9 935.6 ± 443.5  < 0.0001
LED (< 300 mg) 86 (71.1) 2 (11.1) /
LED (> 300 mg) 35 (28.9) 16 (88.9)  < 0.0001
Education, years 8.7 ± 4.6 10.7 ± 4.1 0.08
Presence of MCI 46 (38.0%) 9 (50%) 0.3
Impaired domains
Episodic memory 34 (28.1%) 7 (38.9%) 0.3
Executive functioning 30 (24.8%) 10 (55.6%) 0.01
Attention 36 (29.7%) 4 (22.2%) 0.5
Visuo-spatial function 21 (17.4%) 2 (11.1%) 0.5
Language 1 (0.8%) 1 (5.6%) 0.2
Table 2.  Clinical characteristics at baseline and risk of Levodopa induced dyskinesia at follow-up. LID: 
levodopa induced dyskinesia; UPDRS-ME: Unified Parkinson’s Disease Rating Scale-Motor Examination; LED: 






HR 95%CI p value
Male, n (%) 63 (63.6) 14 (63.6) 1.02 0.43–2.58 0.9
Age, years 66.3 ± 9.3 66.3 ± 8.3 1.01 0.96–1.07 0.5
Age at onset, years 63.9 ± 9.4 62.8 ± 9.4 1.00 0.95–1.05 0.9
Disease duration, years 2.4 ± 2.3 3.5 ± 3.3 1.14 0.99–1.30 0.06
UPDRS-ME score 22.9 ± 11.0 32.9 ± 15.7 1.04 1.01–1.07 0002
LED mg/day (baseline) 210.9 ± 195.1 548.9 ± 430.3 1.002 1.001 ± 1.003  < 0.0001
LED (< 300 mg) 78 (78.8) 6 (27.3) 1 / /
LED (> 300 mg) 21 (21.2) 16 (72.7) 10.1 3.37–30.05  < 0.0001
LED mg/day (follow-up) 499.6 ± 348.5 672.9 ± 588.2 1.0007 1.000–1002 0.1
LED (< 500 mg) 63 (63.6) 13 (59.1) 1 /
LED (> 500 mg) 36 (36.4) 9 (40.9) 1.18 0.49–2.81 0.7
Education, year 9.2 ± 4.6 6.2 ± 3.5 0.80 0.70–0.91 0.001
Presence of MCI 34 (34.3) 12 (54.5) 1.39 0.59–3.29 0.4
Impaired domains at baseline
Episodic memory 28 (28.3) 6 (27.2) 0.50 0.18–1.41 0.2
Executive functioning 20 (20.2) 10 (45.4) 1.99 0.85–4.64 0.1
Attention 26 (26.3) 10 (45.4) 2.67 1.07–6.66 0.03
Visuo-spatial function 15 (15.1) 6 (27.3) 2.08 0.78–5.50 0.1
Language 1 (1.0) 0 / / /
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significant association between the impaired executive functioning domain at baseline and the development of 
LID has been found (HR 3.46; 95%CI 1.26–9.48; p value 0.02) (Supplemental Table 1).
On the other hand, at multivariate analysis (adjusting by age, sex, UPDRS-ME, LED at baseline and education) 
the presence of an impaired attentive domain at baseline strongly predicted the development of LID (HR 4.69; 
95%CI 1.40–15.70; p value 0.01). A close association was also found when the analysis was adjusted by LED at 
follow-up (HR 4.45; 95%CI 1.49–13.23; p value 0.007) (Supplemental Table 2).
In the multivariate analysis concerning the relationship between development of LID and presence of an 
altered visuo-spatial domain at baseline, no association was found in both the models with LED at baseline or 
LED at follow-up.
LID and risk of cognitive impairment. Out of the 84 PD-NC at baseline, 28 (33.3%) developed PD-MCI 
while 4 (4.8%) developed PDD at follow-up. The possible relationship between the presence of LID at baseline 
and the development of MCI at follow-up has been evaluated. At univariate analysis, only age and education 
were significantly associated with the development of PD-MCI. However, at multivariate analysis Cox propor-
tional hazard (adjusting by age, sex, UPDRS-ME, education and LED at follow-up), the presence of LID at base-
line was strongly associated with the development of PD-MCI even if such association was borderline significant 
(HR 4.98; 95%CI 0.93–26.61; p value 0.06) (see Table 3). At baseline out of the 9 PD-NC LID + patients, 7 had 
troublesome LID and of these 3 (42.9%) developed MCI.
Considering the risk of PDD, out of the 139 non-demented patients at baseline, 18 (12.9%) developed PDD 
at follow-up. At univariate analysis, age, UPDRS-ME, education and the presence of PD-MCI at baseline were 
significantly associated with the development of PDD. However, at multivariate analysis (adjusting by LED 
at follow-up, sex, age, education, UPDRS-ME and the presence of PD-MCI), the presence of LID at baseline 
predicted the development of PDD at follow-up (HR 5.58; 95%CI 0.88–35.38; p value 0.06) even if also in this 
case such association was borderline significant, as shown in Table 4. At baseline out of the 18 LID + patients, 11 
(61.1%) had troublesome LID and of these, 2 (18.2%) developed PDD.
Discussion
Our study suggests a bidirectional relationship between LID and cognitive impairment in PD. In particular, the 
impairment of executive and attentive functioning increased the risk of future LID development in PD, while 
the presence of LID at baseline predicts the risk of cognitive impairment.
LID represents a source of distress for PD patients and negatively affects patients’ quality of life and influ-
ences treatment  decisions22. The identification of those patients at greater risk of dyskinesia may result in a bet-
ter clinical approach. Therefore, the interest in evaluating possible predictors of LID is growing. The existence 
Table 3.  Predictors of mild cognitive impairment at follow-up. PD-NC: Parkinson’s disease-normal cognition; 
PD-MCI: Parkinson’s disease-mild cognitive impairment; M: male; UPDRS-ME: Unified Parkinson’s Disease 
Rating Scale-Motor Examination; LED: levodopa equivalent dosage; LID: levodopa induced dyskinesia.
PD-NC (52) PD-MCI (28)
Univariate analysis Multivariate analysis
HR 95%CI p value HR 95%CI p value
Sex (M) 33 (63.4%) 18 (64.3) 1.30 0.58–2.90 0.5 0.93 0.39–2.27 0.9
Age, years 62.2 ± 10.2 68.8 ± 9.8 1.04 1.002–1.09 0.04 1.04 0.99–1.10 0.09
UPDRS-ME 24.6 ± 14.0 24.5 ± 13.0 0.98 0.95–1.01 0.2 0.97 0.94–1.007 0.1
LED at follow-up 643.5 ± 506.4 632.0 ± 446.4 1.00 1.00–1.006 0.5 1.00 0.998–1.0007 0.4
Education, years 10.6 ± 4.1 7.5 ± 4.8 0.90 0.82–0.98 0.02 0.90 0.82–1.00 0.04
LID at baseline 5 (9.6) 3 (10.7) 0.99 0.29–3.31 0.9 4.98 0.93–26.61 0.06
Table 4.  Predictors of Parkinson’s disease-dementia at follow-up. PD-NC: Parkinson’s disease-normal 
cognition; PDD: Parkinson’s disease-dementia; M: men; UPDRS-ME: Unified Parkinson’s Disease Rating 
Scale-Motor Examination; LED: levodopa equivalent dosage; LID: levodopa induced dyskinesia; PD-MCI: 
Parkinson’s disease-mild cognitive impairment.
PD-NC (121) PDD (18)
Univariate analysis Multivariate analysis
HR 95%CI p value HR 95%CI p value
Sex (M) 75 (62.0) 12 (66.7) 1.21 0.43–3.37 0.7 4.80 1.21–19.01 0.02
Age, years 65.3 ± 9.5 68.3 ± 8.4 1.07 1.004–1.151 0.03 1.06 0.98–1.14 0.1
UPDRS-ME score 25.1 ± 12.6 33.1 ± 16.5 1.03 1.00–1.05 0.06 1.03 0.99–1.08 0.09
LED at follow-up 605.0 ± 458.5 603.5 ± 447.9 1.00 1.00–1.001 0.8 1.00 0.998–1.001 0.7
Education, years 9.2 ± 4.5 8.9 ± 4.6 0.88 0.78–0.99 0.04 0.83 0.70–0.97 0.02
LID at baseline 15 (12.4) 3 (16.7) 1.85 0.52–6.56 0.3 5.58 0.88–35.38 0.07
PD-MCI 41(33.9) 14 (77.8) 4.37 1.41–13.50 0.01 8.94 2.07–38.57 0.003
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of an association between LID and cognitive decline is still  controversial9,10. Although LID has recently been 
proposed as risk factor for cognitive  decline11, the role of cognitive impairment in LID occurrence has been 
scarcely investigated.
In particular, two recent longitudinal studies on early PD patients did not find any association between 
the presence of cognitive impairment and LID  occurrence9,10. Similarly, a recent study on PDD and patients 
with Lewy Bodies Disease did not report any association between cognitive impairment and LID  occurrence23. 
However, to the best of our knowledge this is the first longitudinal study assessing the association between the 
presence of cognitive impairment, diagnosed according the currently accepted MDS Level II diagnostic  criteria20 
and LID occurrence.
In agreement with previous  studies9,10, LID+ patients had a younger age at onset, a longer disease duration, 
a more severe motor impairment and took higher levodopa dosages at baseline. Differently for the present data, 
Yoo et al.11 did not find any difference in neuropsychological performances (including those evaluating execu-
tive functioning) at baseline when comparing PD patients with LID at follow-up and PD patients without LID 
at follow-up. Executive functioning (i.e. working memory, flexible thinking, planning, inhibitory control, set-
shifting, decision-making tasks) and attention are cognitive abilities needful for everyday decision-making and 
frequently related to the dopaminergic fronto-striatal  network24,25.
Cognitive impairment and risk of LID. Out of 121 patients LID- at baseline, 18.1% developed LID 
at follow-up. At multivariate analysis, the presence of an impairment in executive functioning and attention 
domains at baseline was strongly associated with LID appearance, with HR of 3.46 and 4.64 (adjusting for age, 
sex, UPDRS-ME, education and LED at follow-up) respectively. Contrarily to what previously  reported9,10, in the 
PACOS cohort the presence of cognitive impairment increased the risk of LID occurrence. However, it should 
be noted that while Kelly and coll. and Euseby and coll. assessed cognitive abilities using only a test of global 
cognition, in the present study the use of a “comprehensive” neuropsychological battery for PD-MCI allowed us 
to explore possible associations between the impairment of specific cognitive domains and LID.
LID and risk of cognitive impairment. Considering the 84 PD-NC at baseline 28 (33.3%) developed 
PD-MCI while 4 developed PDD (4.8%), while regarding the whole sample of 139 non-demented PD patients, 
12.9% developed PDD at follow-up14. PD-MCI was strongly associated with old age and low education level, 
whereas—and as previously  detailed14—the stronger predictor of PDD occurrence was the presence of PD-MCI 
at baseline. In addition to these reported risk factors, in this study we found a strong positive association, even 
if borderline significant, between the presence of LID at baseline and the risk of both PD-MCI (HR 4.98; p value 
0.06) and PDD (HR 5.58; p value 0.07) at follow-up. Despite methodological and study design differences, these 
findings are in agreement with the longitudinal study carried out by Yoo et al., in which the presence of LID 
increased almost four times the risk of conversion to PDD with accelerated executive functioning and global 
cognitive  decline11. Similarly, Zhu et al.26 performed a longitudinal study reporting a mild association between 
the presence of dyskinesia at baseline and the development of PDD after five years after univariate analysis (HR 
1.18); however, the reported association was no longer significant after multivariate analysis.
Although cognitive impairment and dyskinesia represent frequent complications of PD, only few longitudinal 
studies to date have evaluated the association between these two phenomena. To the best of our knowledge, the 
present study represents the first report of an association between the impairment of the executive and attentive 
functioning domains and LID development in PD. The latter association could be related to the dysregulation 
of common cortical network. Indeed, it has been supposed that in PD the decreased inhibitory action of the 
prefrontal cortex on the motor cortex could produce a disinhibition in both motor (involuntary movements) 
and cognitive control loops (loss of inhibitory, self-regulated and goal directed behaviors).
The impairment of attentive and executive functioning has been strictly associated with prefrontal cortex 
dysfunction in PD, due to the striatal dopaminergic degeneration which negatively affects the fronto-striatal 
circuitry in the course of the  disease25. This hypothesis is supported by data from a recent neuropsychological 
and behavioral study in which the authors evaluated the ability to self-regulate in patients with PD, reporting 
higher impulsivity score and lower inhibitory control in PD patients with LID than those  without27. Similarly, in a 
computerized cognitive study using a multiple object tracking paradigm, PD patients even in early stages showed 
an impairment of visuospatial sustained attention, resulting in a difficulty in ignoring non-significant stimuli28.
Actually, the frontal lobe dysfunction in dyskinetic PD patients has been also demonstrated by the reported 
reduction of the connectivity between the right inferior frontal cortex and the left motor  cortex29 as well as the 
greater volume of the right inferior frontal  cortex30.
To deepen the knowledge related to the possible association between cognitive and motor control in PD 
appears to be of considerable interest not only because both phenomena represent a source of distress for PD 
patients, but also for the possible link between the impairment of executive and attentive dysfunction and some 
disinhibitory disorders (i.e. impulse control disorders) belonging, as well as dyskinesia, to anti-parkinsonian 
drugs related side  effects31.
To the best of our knowledge, this is the first longitudinal study assessing the association between the pres-
ence of cognitive impairment, diagnosed according to the current MDS Level II diagnostic  criteria20 and LID 
occurrence in PD. Nevertheless, some limitations should be taken into account when interpreting these findings. 
First, patients were not evaluated with the same follow-up length, which ranged from 12 to 48 months. Thus, this 
variability did not exclude that the absence of dyskinesia in some patients may be due to the shorter duration of 
follow-up. Second, even though the presence of troublesome LID has been evaluated, due to the small number 
of events a statistical analysis evaluating the impact of the severity of dyskinesia on future development of cog-
nitive impairment could not be performed. Third, caution is needed in extending these findings to the general 
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population because the study sample was recruited in a specialized clinical setting, with inherent possibility of 
selection bias. Lastly, although analyses were adjusted for major potential confounders, residual confounding 
cannot be excluded (ie. anxiety and depression, low body mass index at baseline).
However, considering that treating LID or preventing its appearance is possible, our findings may have rel-
evant prognostic and therapeutic implications. Larger prospective cohort studies, with quantitative and qualita-
tive assessment of LID and fixed follow-up time are required to confirm the interplay between LID and cognitive 
impairment in PD.
Ethic approval. The study was approved by the local medical Ethics Committee and was in accordance with 
the Declaration of Helsinki.
Data availability
Anonymized data will be shared by request.
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